MusclePharm Corp. (MSLP) - OTCQB
  • Mon, Jun. 20, 3:42 PM
    • Thinly traded micro cap ChromaDex (CDXC -41.6%) craters on a 22x surge in volume in response to an article published today on Seeking Alpha by Bleecker Street Research that details the company's connection with stock promoter Barry Honig (among his stable of companies is MusclePharm (OTCQB:MSLP -2.1%)).
    • Bleecker says the company is due for a major correction (clearly underway today) which has the been the hallmark of other Honig investments like Pershing Gold, Chanticleer Holdings, Sevion Therapeutics, Cocrystal Pharma and Spherix.
    • Update: In an 8-K filed on June 24, the company reported that board member William Smithburg resigned on June 20, prompted by Bleecker Street's article. Mr. Smithburg informed the company that "at this stage of his life he was unable to be involved as a board member in any company that was the subject of a malicious attack of this nature" although he also told the company that he intended to continue supporting the firm as an investor. As of June 14, he owned 640K shares.
    • Update: On June 30, an announcement was made that the article was removed from SA and replaced by an apology by Bleecker admitting that it was misleading.
    | Mon, Jun. 20, 3:42 PM | 25 Comments
  • Wed, May 25, 4:57 PM
    • With the aim of cutting expenses, struggling sports nutrition firm MusclePharm (OTCQB:MSLP) terminates its endorsement deal with golfer Tiger Woods. The chronically cash-poor company is mired in lawsuits as it attempts to stabilize its business. Supplier Capstone Nutrition filed a $65M breach of contract suit a few days ago.
    • Shares were down over 10% today before recovering.
    • Update: The company agreed to pay $2.5M to terminate the contract with Mr. Woods and eliminate all future costs and obligations, a good deal considering it owed $7M.
    | Wed, May 25, 4:57 PM | 28 Comments
  • Nov. 10, 2015, 11:11 AM
    • Sports nutrition products maker MusclePharm (OTCQB:MSLP -15.4%) slumps after posting yet another quarter of poor financial results. Revenues were down almost 30% while operating expenses climbed 92%. Cash on hand is a paltry $3.5M.
    • Management has launched a major restructuring in an effort to turn the business around. Prior guidance has been withdrawn and will no longer be provided.
    | Nov. 10, 2015, 11:11 AM | 18 Comments
  • Mar. 17, 2015, 10:48 AM
    | Mar. 17, 2015, 10:48 AM | 33 Comments
  • Nov. 17, 2014, 10:52 AM
    • Sports nutrition firm MusclePharm (OTCQB:MSLP -16.1%) slumps on light turnover of 132K shares in response to its Q3 earnings report after Friday's close. EPS of $0.05 missed estimates by $0.29. Also, its cash balance is only $2.9M.
    • Management affirms its full-year revenue guidance of $185M - 195M, but revises its EPS guidance to $0.20 - 0.22.
    | Nov. 17, 2014, 10:52 AM | 1 Comment
Company Description
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufactures a full line of NSF and scientifically approved nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States